Optinose Announces Reporting Date for Third Quarter 2021 Financial Results
10 nov. 2021 17h50 HE
|
Optinose, Inc.
Conference Call and Webcast to be held November 16, 2021 at 8:30 a.m. Eastern Time YARDLEY, Pa., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on...
Optinose Completes Patient Recruitment in Second Pivotal Trial for XHANCE in Chronic Sinusitis
28 oct. 2021 06h59 HE
|
Optinose, Inc.
Company Expects Top-Line Results in Second Quarter 2022 XHANCE Reaches Important Milestone on Path to be the First FDA-Approved Drug Treatment for the Approximately 30 million Chronic Sinusitis...
Optinose to Present at the Cantor Virtual Global Healthcare Conference
22 sept. 2021 16h15 HE
|
Optinose, Inc.
YARDLEY, Pa., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Vallon Pharmaceuticals Appoints Leanne Kelly as Chief Financial Officer
11 mai 2021 09h05 HE
|
Vallon Pharmaceuticals Inc.
- Financial executive bringing over 20 years of experience in accounting, finance and management with a foundation established from big four accounting firm PHILADELPHIA, PA, May 11, 2021 ...
Optinose Reports First Quarter 2021 Financial Results and Operational Updates
05 mai 2021 07h00 HE
|
Optinose, Inc.
Company reports first quarter total revenue of $12.0 million First quarter 2021 XHANCE net revenue of $11.0 million increased 55% compared to first quarter 2020 Conference call and webcast to be...
Optinose Announces Reporting Date for First Quarter 2021 Financial Results and Upcoming Healthcare Conference Presentation
28 avr. 2021 08h30 HE
|
Optinose, Inc.
Conference Call and Webcast to be held May 5, 2021 at 8:00 a.m. Eastern Time Company to Present at the RBC Capital Markets Global Healthcare Conference on May 18, 2021 YARDLEY, Pa., April 28, 2021...
Optinose Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Operational Highlights
03 mars 2021 07h00 HE
|
Optinose, Inc.
Company reports fourth quarter and full year 2020 XHANCE net revenue of $15.6 million and $48.4 million Full year 2020 XHANCE prescriptions increased 70% compared to full year 2019 Company...
Optinose to Present at Jefferies 2017 London Healthcare Conference
08 nov. 2017 08h00 HE
|
OptiNose, Inc.
YARDLEY, Pa., Nov. 08, 2017 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ENT and allergy specialists, today announced that Chief Executive...